Perforator Vein Injection for Symptomatic Venous Disease

Venous Disease Clinical Trial

— Dillavou  

Official title:

Randomized Trial of Perforator Vein Injection for Symptomatic Venous Disease

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03363633
• Other study ID #: Protocol #4
• Status: Terminated
• Phase: N/A
• First received: June 4, 2017
• Last updated: February 21, 2018
• Start date: March 2010
• Est. completion date: October 1, 2010

Study information

• Verified date: February 2018
• Source: University of Pittsburgh
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary objective of this study is to compare two treatment strategies for symptomatic venous stasis disease with and without venous ulcer. These treatments are compression therapy alone vs. sclerotherapy of refluxing perforating veins with compression.

Description:

Symptomatic venous disease is a widespread problem, affecting millions of patients per year, an estimated 1.0 - 1.5% of the population. This costs up to 1% of the total health care budget1-3. Venous problems account for almost 3000 patient visits in the UPP vascular surgery group per year. Although great progress has been made in venous stasis treatments there are still patients who suffer for many years with pain and ulceration due to venous disease. The investigators believe that venous hypertension is the underlying cause of venous ulceration. Three mechanisms leading to venous hypertension are well-recognized: superficial vein (great, accessory and small saphenous) incompetence; deep vein (common and superficial femoral, popliteal and tibial) reflux or obstruction; perforating vein incompetence. Patients with venous stasis and ulceration may have any or all of these conditions. Currently there are excellent treatments for superficial venous reflux, namely laser or radiofrequency ablation. Deep venous reflux therapy is still under investigation, with prosthetic valves in trial. However, compression is still the mainstay of therapy. The presence of deep venous reflux has been shown to have a significant effect on ulcer healing when perforator treatment has been investigated4. Refluxing perforator vein treatment is currently in flux, with the existing options of open surgery and subfascial endoscopic perforator surgery (SEPS) being the most tested options, but with significant wound complications and long hospital stays associated with both7. The investigators are proposing a prospective trial to evaluate percutaneous perforator thrombosis to achieve similar results with less morbidity.

The population targeted is patients with venous stasis or ulceration who either do not have demonstrable superficial reflux amenable to ablation, or have venous symptoms and ulceration despite treatment of incompetent superficial veins. When patients have refluxing perforating veins, there is debate on optimal treatment. Open and endoscopic ligation and compression therapy have all been tried with varying degrees of success and morbidity. The average rate of healing in venous ulcers is approximately .05 cm/wk 5,6, which has been shown to significantly improve after perforator ligation4, but with high morbidity. Ultrasound-guided injection of perforating veins is now performed, but with largely unknown benefits and consequences. The investigators propose a prospective, randomized trial of perforator injection with sodium tetradecyl sulfate (STS) foam vs. compression as a means of determining the efficacy and morbidity of perforator STS foam injection for symptomatic venous disease. The investigators currently utilize both methods of treatment in practice. Injections and compression or compression alone are chosen based on each patient's clinical scenario. STS is currently approved by the U.S. Food and Drug Administration for intravenous use.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 12
• Est. completion date: October 1, 2010
• Est. primary completion date: October 1, 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• • The subject must be > 18 years of age, male or female

• Subject must be willing and able to wear compression stockings

• Subject must have refluxing perforating veins = 3.0 mm in diameter at the calf level or distally in the affected leg.

• Subject presents with ulceration or other symptoms of venous stasis including:

rash, swelling, pain, bleeding, recurrent cellulitis

• The subject must sign a written informed consent, prior to randomization, using a form that is approved by the local Institutional Review Board.

Exclusion Criteria:

• • Pregnancy

• Known allergy to STS

• Refusal to wear compression stocking

• Untreated significant great or small saphenous reflux

• Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.

• Significant arterial disease (ABI < .8)

• Buergers disease

• Acute superficial thrombophlebitis

• Phlebitis migrans

• Acute cellulitis

• Clinical evidence of active local or systemic infection

Related Conditions & MeSH terms

• Venous Disease

Intervention

Drug:
• sodium tetradecyl sulfate
Ultrasound-guided injection with sodium tetradecyl sulfate foam of refluxing perforating veins

Device:
• Compression
20-30 mmHg compression stockings

Locations

Country	Name	City	State
United States	Shadyside Medical Building, Suite 307	Pittsburgh	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
Ellen Dillavou	American College of Phlebology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Ulcer Healing	Change in wound size, reported in square centimeters	12 months
Secondary	Venous Clinical Severity Score (VCSS)	The VCSS includes nine criteria of chronic venous disease, each graded from 0 to 3 (0=absent, 1=mild, 2=moderate, 3=severe). Up to three points may be added for differences in background conservative therapy (compression and elevation). The scores are then added, with a maximum score of 30.	12 months
Secondary	Injection Complications	Number of participants experiencing venous thromboses from injections	12 months
Secondary	Compliance With Compression Therapy	Number of participants who use compression therapy	12 months
Secondary	Ulcer Recurrence	Number of participants with ulcers that reopen after initial closure	12 months